#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=4. Discussion
1-1	0-2	4.	_	_	_	_
1-2	3-13	Discussion	abstract	new	_	_

#Text=In the present study , we performed 16s rRNA deep sequencing and obtained large amounts of data concerning the microbial composition , diversity , and abundance in healthy subjects and RA patients with various clinical phenotypes .
2-1	14-16	In	_	_	_	_
2-2	17-20	the	abstract[2]	new[2]	coref	10-26[87_2]
2-3	21-28	present	abstract[2]	new[2]	_	_
2-4	29-34	study	abstract[2]	new[2]	_	_
2-5	35-36	,	_	_	_	_
2-6	37-39	we	person	acc	ana	8-1
2-7	40-49	performed	_	_	_	_
2-8	50-53	16s	abstract|abstract[5]|abstract[6]	new|new[5]|new[6]	_	_
2-9	54-58	rRNA	abstract[5]|abstract[6]	new[5]|new[6]	_	_
2-10	59-63	deep	abstract[6]	new[6]	_	_
2-11	64-74	sequencing	abstract[6]	new[6]	_	_
2-12	75-78	and	_	_	_	_
2-13	79-87	obtained	_	_	_	_
2-14	88-93	large	abstract[7]	new[7]	_	_
2-15	94-101	amounts	abstract[7]	new[7]	_	_
2-16	102-104	of	abstract[7]	new[7]	_	_
2-17	105-109	data	abstract[7]|abstract[8]	new[7]|new[8]	coref	11-1[89_8]
2-18	110-120	concerning	abstract[7]|abstract[8]	new[7]|new[8]	_	_
2-19	121-124	the	abstract[7]|abstract[8]|abstract[9]	new[7]|new[8]|new[9]	coref	7-7[59_9]
2-20	125-134	microbial	abstract[7]|abstract[8]|abstract[9]	new[7]|new[8]|new[9]	_	_
2-21	135-146	composition	abstract[7]|abstract[8]|abstract[9]	new[7]|new[8]|new[9]	_	_
2-22	147-148	,	abstract[7]|abstract[8]	new[7]|new[8]	_	_
2-23	149-158	diversity	abstract[7]|abstract[8]|abstract	new[7]|new[8]|new	_	_
2-24	159-160	,	abstract[7]|abstract[8]	new[7]|new[8]	_	_
2-25	161-164	and	abstract[7]|abstract[8]	new[7]|new[8]	_	_
2-26	165-174	abundance	abstract[7]|abstract[8]|abstract[11]	new[7]|new[8]|new[11]	coref	3-6[18_11]
2-27	175-177	in	abstract[7]|abstract[8]|abstract[11]	new[7]|new[8]|new[11]	_	_
2-28	178-185	healthy	abstract[7]|abstract[8]|abstract[11]|animal[12]|animal[13]	new[7]|new[8]|new[11]|new[12]|new[13]	coref|coref	3-19[24_12]|14-8[111_13]
2-29	186-194	subjects	abstract[7]|abstract[8]|abstract[11]|animal[12]|animal[13]	new[7]|new[8]|new[11]|new[12]|new[13]	_	_
2-30	195-198	and	abstract[7]|abstract[8]|abstract[11]|animal[13]	new[7]|new[8]|new[11]|new[13]	_	_
2-31	199-201	RA	abstract[7]|abstract[8]|abstract[11]|animal[13]|organization|person[15]	new[7]|new[8]|new[11]|new[13]|new|new[15]	coref|coref	3-15|3-15[23_15]
2-32	202-210	patients	abstract[7]|abstract[8]|abstract[11]|animal[13]|person[15]	new[7]|new[8]|new[11]|new[13]|new[15]	_	_
2-33	211-215	with	abstract[7]|abstract[8]|abstract[11]|animal[13]|person[15]	new[7]|new[8]|new[11]|new[13]|new[15]	_	_
2-34	216-223	various	abstract[7]|abstract[8]|abstract[11]|animal[13]|person[15]|abstract[16]	new[7]|new[8]|new[11]|new[13]|new[15]|new[16]	coref	4-29[38_16]
2-35	224-232	clinical	abstract[7]|abstract[8]|abstract[11]|animal[13]|person[15]|abstract[16]	new[7]|new[8]|new[11]|new[13]|new[15]|new[16]	_	_
2-36	233-243	phenotypes	abstract[7]|abstract[8]|abstract[11]|animal[13]|person[15]|abstract[16]	new[7]|new[8]|new[11]|new[13]|new[15]|new[16]	_	_
2-37	244-245	.	_	_	_	_

#Text=The results have demonstrated that a lower abundance and evenness of gut microbiota in RA patients compared with healthy subjects , with α-diversity lower in RF-positive or ACPA-positive RA patients than healthy subjects .
3-1	246-249	The	abstract[17]	new[17]	coref	18-4[162_17]
3-2	250-257	results	abstract[17]	new[17]	_	_
3-3	258-262	have	_	_	_	_
3-4	263-275	demonstrated	_	_	_	_
3-5	276-280	that	_	_	_	_
3-6	281-282	a	abstract[18]	giv[18]	coref	6-15[51_18]
3-7	283-288	lower	abstract[18]	giv[18]	_	_
3-8	289-298	abundance	abstract[18]	giv[18]	_	_
3-9	299-302	and	_	_	_	_
3-10	303-311	evenness	abstract[19]	new[19]	_	_
3-11	312-314	of	abstract[19]	new[19]	_	_
3-12	315-318	gut	abstract[19]|abstract|substance[21]	new[19]|new|new[21]	coref|coref	4-15|4-15[34_21]
3-13	319-329	microbiota	abstract[19]|substance[21]	new[19]|new[21]	_	_
3-14	330-332	in	abstract[19]|substance[21]	new[19]|new[21]	_	_
3-15	333-335	RA	abstract[19]|substance[21]|organization|person[23]	new[19]|new[21]|giv|giv[23]	coref|coref	3-29|3-26[27_23]
3-16	336-344	patients	abstract[19]|substance[21]|person[23]	new[19]|new[21]|giv[23]	_	_
3-17	345-353	compared	abstract[19]	new[19]	_	_
3-18	354-358	with	abstract[19]	new[19]	_	_
3-19	359-366	healthy	abstract[19]|animal[24]	new[19]|giv[24]	coref	3-32[28_24]
3-20	367-375	subjects	abstract[19]|animal[24]	new[19]|giv[24]	_	_
3-21	376-377	,	_	_	_	_
3-22	378-382	with	_	_	_	_
3-23	383-394	α-diversity	abstract	new	coref	8-11[66_0]
3-24	395-400	lower	_	_	_	_
3-25	401-403	in	_	_	_	_
3-26	404-415	RF-positive	person[27]	giv[27]	coref	4-26[37_27]
3-27	416-418	or	person[27]	giv[27]	_	_
3-28	419-432	ACPA-positive	person[27]	giv[27]	_	_
3-29	433-435	RA	organization|person[27]	giv|giv[27]	coref	4-26
3-30	436-444	patients	person[27]	giv[27]	_	_
3-31	445-449	than	_	_	_	_
3-32	450-457	healthy	animal[28]	giv[28]	coref	4-18[35_28]
3-33	458-466	subjects	animal[28]	giv[28]	_	_
3-34	467-468	.	_	_	_	_

#Text=Using the permutational multivariate analysis of variance ( PERMANOVA ) , the β-diversity of gut microbiota in healthy subjects was significantly different from that in RA patients with different phenotypes .
4-1	469-474	Using	_	_	_	_
4-2	475-478	the	abstract[29]	new[29]	appos	4-9[0_29]
4-3	479-492	permutational	abstract[29]	new[29]	_	_
4-4	493-505	multivariate	abstract[29]	new[29]	_	_
4-5	506-514	analysis	abstract[29]	new[29]	_	_
4-6	515-517	of	abstract[29]	new[29]	_	_
4-7	518-526	variance	abstract[29]|abstract	new[29]|new	_	_
4-8	527-528	(	_	_	_	_
4-9	529-538	PERMANOVA	abstract	giv	coref	14-15
4-10	539-540	)	_	_	_	_
4-11	541-542	,	_	_	_	_
4-12	543-546	the	abstract[32]	new[32]	coref	14-5[109_32]
4-13	547-558	β-diversity	abstract[32]	new[32]	_	_
4-14	559-561	of	abstract[32]	new[32]	_	_
4-15	562-565	gut	abstract[32]|abstract|substance[34]	new[32]|giv|giv[34]	coref|coref	8-15|9-5[75_34]
4-16	566-576	microbiota	abstract[32]|substance[34]	new[32]|giv[34]	_	_
4-17	577-579	in	abstract[32]	new[32]	_	_
4-18	580-587	healthy	abstract[32]|animal[35]	new[32]|giv[35]	coref	5-15[44_35]
4-19	588-596	subjects	abstract[32]|animal[35]	new[32]|giv[35]	_	_
4-20	597-600	was	_	_	_	_
4-21	601-614	significantly	_	_	_	_
4-22	615-624	different	_	_	_	_
4-23	625-629	from	_	_	_	_
4-24	630-634	that	_	_	_	_
4-25	635-637	in	_	_	_	_
4-26	638-640	RA	organization|person[37]	giv|giv[37]	coref|coref	5-11|5-11[43_37]
4-27	641-649	patients	person[37]	giv[37]	_	_
4-28	650-654	with	person[37]	giv[37]	_	_
4-29	655-664	different	person[37]|abstract[38]	giv[37]|giv[38]	coref	11-25[95_38]
4-30	665-675	phenotypes	person[37]|abstract[38]	giv[37]|giv[38]	_	_
4-31	676-677	.	_	_	_	_

#Text=The phylum Verrucomicrobiae and genus Akkermansia were more abundant in RA patients compared with healthy subjects .
5-1	678-681	The	abstract[39]|abstract[40]	new[39]|new[40]	_	_
5-2	682-688	phylum	abstract[39]|abstract[40]	new[39]|new[40]	_	_
5-3	689-705	Verrucomicrobiae	abstract[40]	new[40]	_	_
5-4	706-709	and	_	_	_	_
5-5	710-715	genus	animal	new	coref	17-30[154_0]
5-6	716-727	Akkermansia	_	_	_	_
5-7	728-732	were	_	_	_	_
5-8	733-737	more	_	_	_	_
5-9	738-746	abundant	_	_	_	_
5-10	747-749	in	_	_	_	_
5-11	750-752	RA	organization|person[43]	giv|giv[43]	coref|coref	6-2|6-2[46_43]
5-12	753-761	patients	person[43]	giv[43]	_	_
5-13	762-770	compared	_	_	_	_
5-14	771-775	with	_	_	_	_
5-15	776-783	healthy	animal[44]	giv[44]	coref	8-19[69_44]
5-16	784-792	subjects	animal[44]	giv[44]	_	_
5-17	793-794	.	_	_	_	_

#Text=Among RA patients , those with higher levels of TNF-α or IL-17A had increased the relative abundance of the phylum Gammaproteobacteria compared to those with lower cytokine levels .
6-1	795-800	Among	_	_	_	_
6-2	801-803	RA	organization|person[46]	giv|giv[46]	coref|coref	7-4|7-4[58_46]
6-3	804-812	patients	person[46]	giv[46]	_	_
6-4	813-814	,	_	_	_	_
6-5	815-820	those	person[47]	acc[47]	ana	6-24[54_47]
6-6	821-825	with	person[47]	acc[47]	_	_
6-7	826-832	higher	person[47]|abstract[48]	acc[47]|new[48]	_	_
6-8	833-839	levels	person[47]|abstract[48]	acc[47]|new[48]	_	_
6-9	840-842	of	person[47]|abstract[48]	acc[47]|new[48]	_	_
6-10	843-848	TNF-α	person[47]|abstract[48]|abstract	acc[47]|new[48]|new	coref	16-21
6-11	849-851	or	person[47]|abstract[48]	acc[47]|new[48]	_	_
6-12	852-858	IL-17A	person[47]|abstract[48]|abstract	acc[47]|new[48]|new	coref	16-23
6-13	859-862	had	_	_	_	_
6-14	863-872	increased	_	_	_	_
6-15	873-876	the	abstract[51]	giv[51]	coref	15-10[0_51]
6-16	877-885	relative	abstract[51]	giv[51]	_	_
6-17	886-895	abundance	abstract[51]	giv[51]	_	_
6-18	896-898	of	abstract[51]	giv[51]	_	_
6-19	899-902	the	abstract[51]|person[52]|abstract[53]	giv[51]|new[52]|new[53]	coref	17-22[153_52]
6-20	903-909	phylum	abstract[51]|person[52]|abstract[53]	giv[51]|new[52]|new[53]	_	_
6-21	910-929	Gammaproteobacteria	abstract[51]|abstract[53]	giv[51]|new[53]	_	_
6-22	930-938	compared	_	_	_	_
6-23	939-941	to	_	_	_	_
6-24	942-947	those	person[54]	giv[54]	_	_
6-25	948-952	with	person[54]	giv[54]	_	_
6-26	953-958	lower	person[54]|abstract[56]	giv[54]|new[56]	coref	16-14[136_56]
6-27	959-967	cytokine	person[54]|abstract|abstract[56]	giv[54]|new|new[56]	_	_
6-28	968-974	levels	person[54]|abstract[56]	giv[54]|new[56]	_	_
6-29	975-976	.	_	_	_	_

#Text=In addition , RA patients exhibited a different microbial composition which was related to RF/ACPA seropositivity .
7-1	977-979	In	_	_	_	_
7-2	980-988	addition	_	_	_	_
7-3	989-990	,	_	_	_	_
7-4	991-993	RA	organization|person[58]	giv|giv[58]	coref|coref	8-2|8-1[64_58]
7-5	994-1002	patients	person[58]	giv[58]	_	_
7-6	1003-1012	exhibited	_	_	_	_
7-7	1013-1014	a	abstract[59]	giv[59]	coref	16-29[142_59]
7-8	1015-1024	different	abstract[59]	giv[59]	_	_
7-9	1025-1034	microbial	abstract[59]	giv[59]	_	_
7-10	1035-1046	composition	abstract[59]	giv[59]	_	_
7-11	1047-1052	which	abstract[59]	giv[59]	_	_
7-12	1053-1056	was	abstract[59]	giv[59]	_	_
7-13	1057-1064	related	abstract[59]	giv[59]	_	_
7-14	1065-1067	to	abstract[59]	giv[59]	_	_
7-15	1068-1075	RF/ACPA	abstract[59]|organization|abstract[61]	giv[59]|new|new[61]	coref	14-29
7-16	1076-1090	seropositivity	abstract[59]|abstract[61]	giv[59]|new[61]	_	_
7-17	1091-1092	.	_	_	_	_

#Text=Our RA patients in either active or inactive status had a lower α-diversity of gut microbial taxa than healthy subjects , consistent with the findings in Korean patients with early RA .
8-1	1093-1096	Our	person|person[64]	giv|giv[64]	coref|ana	8-27[71_64]|11-1
8-2	1097-1099	RA	organization|person[64]	giv|giv[64]	coref	8-30[72_0]
8-3	1100-1108	patients	person[64]	giv[64]	_	_
8-4	1109-1111	in	person[64]	giv[64]	_	_
8-5	1112-1118	either	person[64]|abstract[65]	giv[64]|new[65]	coref	14-29[121_65]
8-6	1119-1125	active	person[64]|abstract[65]	giv[64]|new[65]	_	_
8-7	1126-1128	or	person[64]|abstract[65]	giv[64]|new[65]	_	_
8-8	1129-1137	inactive	person[64]|abstract[65]	giv[64]|new[65]	_	_
8-9	1138-1144	status	person[64]|abstract[65]	giv[64]|new[65]	_	_
8-10	1145-1148	had	_	_	_	_
8-11	1149-1150	a	abstract[66]	giv[66]	_	_
8-12	1151-1156	lower	abstract[66]	giv[66]	_	_
8-13	1157-1168	α-diversity	abstract[66]	giv[66]	_	_
8-14	1169-1171	of	abstract[66]	giv[66]	_	_
8-15	1172-1175	gut	abstract[66]|abstract|abstract[68]	giv[66]|giv|new[68]	coref	9-5
8-16	1176-1185	microbial	abstract[66]|abstract[68]	giv[66]|new[68]	_	_
8-17	1186-1190	taxa	abstract[66]|abstract[68]	giv[66]|new[68]	_	_
8-18	1191-1195	than	_	_	_	_
8-19	1196-1203	healthy	animal[69]	giv[69]	coref	14-8[110_69]
8-20	1204-1212	subjects	animal[69]	giv[69]	_	_
8-21	1213-1214	,	_	_	_	_
8-22	1215-1225	consistent	_	_	_	_
8-23	1226-1230	with	_	_	_	_
8-24	1231-1234	the	abstract[70]	new[70]	coref	10-6[79_70]
8-25	1235-1243	findings	abstract[70]	new[70]	_	_
8-26	1244-1246	in	abstract[70]	new[70]	_	_
8-27	1247-1253	Korean	abstract[70]|person[71]	new[70]|giv[71]	coref	9-10[76_71]
8-28	1254-1262	patients	abstract[70]|person[71]	new[70]|giv[71]	_	_
8-29	1263-1267	with	abstract[70]|person[71]	new[70]|giv[71]	_	_
8-30	1268-1273	early	abstract[70]|person[71]|organization[72]	new[70]|giv[71]|giv[72]	coref	10-19[0_72]
8-31	1274-1276	RA	abstract[70]|person[71]|organization[72]	new[70]|giv[71]|giv[72]	_	_
8-32	1277-1278	.	_	_	_	_

#Text=Moreover , α-diversity of gut microbiota was lower in ACPA-positive patients compared to HC .
9-1	1279-1287	Moreover	_	_	_	_
9-2	1288-1289	,	_	_	_	_
9-3	1290-1301	α-diversity	abstract[73]	new[73]	coref	10-13[0_73]
9-4	1302-1304	of	abstract[73]	new[73]	_	_
9-5	1305-1308	gut	abstract[73]|abstract|substance[75]	new[73]|giv|giv[75]	coref|coref	16-29|16-30[0_75]
9-6	1309-1319	microbiota	abstract[73]|substance[75]	new[73]|giv[75]	_	_
9-7	1320-1323	was	_	_	_	_
9-8	1324-1329	lower	_	_	_	_
9-9	1330-1332	in	_	_	_	_
9-10	1333-1346	ACPA-positive	person[76]	giv[76]	ana	10-18[0_76]
9-11	1347-1355	patients	person[76]	giv[76]	_	_
9-12	1356-1364	compared	_	_	_	_
9-13	1365-1367	to	_	_	_	_
9-14	1368-1370	HC	animal	new	_	_
9-15	1371-1372	.	_	_	_	_

#Text=Although Chen et al. revealed similar findings , the significant association of α-diversity with ACPA positivity in their RA patients could not be reproduced in the present study .
10-1	1373-1381	Although	_	_	_	_
10-2	1382-1386	Chen	person	new	coref	25-1
10-3	1387-1389	et	_	_	_	_
10-4	1390-1393	al.	_	_	_	_
10-5	1394-1402	revealed	_	_	_	_
10-6	1403-1410	similar	abstract[79]	giv[79]	coref	18-1[161_79]
10-7	1411-1419	findings	abstract[79]	giv[79]	_	_
10-8	1420-1421	,	_	_	_	_
10-9	1422-1425	the	abstract[80]	new[80]	_	_
10-10	1426-1437	significant	abstract[80]	new[80]	_	_
10-11	1438-1449	association	abstract[80]	new[80]	_	_
10-12	1450-1452	of	abstract[80]	new[80]	_	_
10-13	1453-1464	α-diversity	abstract[80]|abstract	new[80]|giv	coref	13-14[105_0]
10-14	1465-1469	with	abstract[80]	new[80]	_	_
10-15	1470-1474	ACPA	abstract[80]|abstract|abstract[83]	new[80]|new|new[83]	coref	12-7
10-16	1475-1485	positivity	abstract[80]|abstract[83]	new[80]|new[83]	_	_
10-17	1486-1488	in	abstract[80]	new[80]	_	_
10-18	1489-1494	their	abstract[80]|person|person[86]	new[80]|giv|giv[86]	coref|coref	10-18[86_0]|13-5[103_86]
10-19	1495-1497	RA	abstract[80]|organization|person[86]	new[80]|giv|giv[86]	coref	11-22
10-20	1498-1506	patients	abstract[80]|person[86]	new[80]|giv[86]	_	_
10-21	1507-1512	could	_	_	_	_
10-22	1513-1516	not	_	_	_	_
10-23	1517-1519	be	_	_	_	_
10-24	1520-1530	reproduced	_	_	_	_
10-25	1531-1533	in	_	_	_	_
10-26	1534-1537	the	abstract[87]	giv[87]	coref	24-23[226_87]
10-27	1538-1545	present	abstract[87]	giv[87]	_	_
10-28	1546-1551	study	abstract[87]	giv[87]	_	_
10-29	1552-1553	.	_	_	_	_

#Text=Our statistical data has suggested that there was no significant difference which may be due to the small sample size of RA subgroups with different phenotypes .
11-1	1554-1557	Our	person|abstract[89]	giv|giv[89]	ana	17-16
11-2	1558-1569	statistical	abstract[89]	giv[89]	_	_
11-3	1570-1574	data	abstract[89]	giv[89]	_	_
11-4	1575-1578	has	_	_	_	_
11-5	1579-1588	suggested	_	_	_	_
11-6	1589-1593	that	_	_	_	_
11-7	1594-1599	there	_	_	_	_
11-8	1600-1603	was	_	_	_	_
11-9	1604-1606	no	abstract[90]	new[90]	coref	14-2[108_90]
11-10	1607-1618	significant	abstract[90]	new[90]	_	_
11-11	1619-1629	difference	abstract[90]	new[90]	_	_
11-12	1630-1635	which	abstract[90]	new[90]	_	_
11-13	1636-1639	may	abstract[90]	new[90]	_	_
11-14	1640-1642	be	abstract[90]	new[90]	_	_
11-15	1643-1646	due	abstract[90]	new[90]	_	_
11-16	1647-1649	to	abstract[90]	new[90]	_	_
11-17	1650-1653	the	abstract[90]|abstract[92]	new[90]|new[92]	_	_
11-18	1654-1659	small	abstract[90]|abstract[92]	new[90]|new[92]	_	_
11-19	1660-1666	sample	abstract[90]|object|abstract[92]	new[90]|new|new[92]	_	_
11-20	1667-1671	size	abstract[90]|abstract[92]	new[90]|new[92]	_	_
11-21	1672-1674	of	abstract[90]|abstract[92]	new[90]|new[92]	_	_
11-22	1675-1677	RA	abstract[90]|abstract[92]|organization|abstract[94]	new[90]|new[92]|giv|new[94]	coref	14-11
11-23	1678-1687	subgroups	abstract[90]|abstract[92]|abstract[94]	new[90]|new[92]|new[94]	_	_
11-24	1688-1692	with	abstract[90]|abstract[92]|abstract[94]	new[90]|new[92]|new[94]	_	_
11-25	1693-1702	different	abstract[90]|abstract[92]|abstract[94]|abstract[95]	new[90]|new[92]|new[94]|giv[95]	coref	14-22[117_95]
11-26	1703-1713	phenotypes	abstract[90]|abstract[92]|abstract[94]|abstract[95]	new[90]|new[92]|new[94]|giv[95]	_	_
11-27	1714-1715	.	_	_	_	_

#Text=In addition , the production of ACPA may be multifactorial , such as genetic factor , smoking , and the severity of periodontitis .
12-1	1716-1718	In	_	_	_	_
12-2	1719-1727	addition	_	_	_	_
12-3	1728-1729	,	_	_	_	_
12-4	1730-1733	the	abstract[96]	new[96]	_	_
12-5	1734-1744	production	abstract[96]	new[96]	_	_
12-6	1745-1747	of	abstract[96]	new[96]	_	_
12-7	1748-1752	ACPA	abstract[96]|abstract	new[96]|giv	_	_
12-8	1753-1756	may	_	_	_	_
12-9	1757-1759	be	_	_	_	_
12-10	1760-1774	multifactorial	_	_	_	_
12-11	1775-1776	,	_	_	_	_
12-12	1777-1781	such	_	_	_	_
12-13	1782-1784	as	_	_	_	_
12-14	1785-1792	genetic	abstract[98]	new[98]	_	_
12-15	1793-1799	factor	abstract[98]	new[98]	_	_
12-16	1800-1801	,	_	_	_	_
12-17	1802-1809	smoking	event	new	_	_
12-18	1810-1811	,	_	_	_	_
12-19	1812-1815	and	_	_	_	_
12-20	1816-1819	the	abstract[100]	new[100]	_	_
12-21	1820-1828	severity	abstract[100]	new[100]	_	_
12-22	1829-1831	of	abstract[100]	new[100]	_	_
12-23	1832-1845	periodontitis	abstract[100]|abstract	new[100]|new	_	_
12-24	1846-1847	.	_	_	_	_

#Text=After the pooling of RF-positive and ACPA-positive patients in a single goup , a significantly lower α-diversity was observed in seropositive patients compared to seronegative patients .
13-1	1848-1853	After	_	_	_	_
13-2	1854-1857	the	abstract[102]	new[102]	_	_
13-3	1858-1865	pooling	abstract[102]	new[102]	_	_
13-4	1866-1868	of	abstract[102]	new[102]	_	_
13-5	1869-1880	RF-positive	abstract[102]|person[103]	new[102]|giv[103]	coref	13-21[106_103]
13-6	1881-1884	and	abstract[102]|person[103]	new[102]|giv[103]	_	_
13-7	1885-1898	ACPA-positive	abstract[102]|person[103]	new[102]|giv[103]	_	_
13-8	1899-1907	patients	abstract[102]|person[103]	new[102]|giv[103]	_	_
13-9	1908-1910	in	abstract[102]	new[102]	_	_
13-10	1911-1912	a	abstract[102]|event[104]	new[102]|new[104]	_	_
13-11	1913-1919	single	abstract[102]|event[104]	new[102]|new[104]	_	_
13-12	1920-1924	goup	abstract[102]|event[104]	new[102]|new[104]	_	_
13-13	1925-1926	,	_	_	_	_
13-14	1927-1928	a	abstract[105]	giv[105]	_	_
13-15	1929-1942	significantly	abstract[105]	giv[105]	_	_
13-16	1943-1948	lower	abstract[105]	giv[105]	_	_
13-17	1949-1960	α-diversity	abstract[105]	giv[105]	_	_
13-18	1961-1964	was	_	_	_	_
13-19	1965-1973	observed	_	_	_	_
13-20	1974-1976	in	_	_	_	_
13-21	1977-1989	seropositive	person[106]	giv[106]	coref	13-25[107_106]
13-22	1990-1998	patients	person[106]	giv[106]	_	_
13-23	1999-2007	compared	person[106]	giv[106]	_	_
13-24	2008-2010	to	person[106]	giv[106]	_	_
13-25	2011-2023	seronegative	person[106]|person[107]	giv[106]|giv[107]	coref	14-11[113_107]
13-26	2024-2032	patients	person[106]|person[107]	giv[106]|giv[107]	_	_
13-27	2033-2034	.	_	_	_	_

#Text=Regarding the difference in the β-diversity between healthy subjects and RA patients , the PERMANOVA analysis showed a significant difference in phenotypes characterized by different disease activity and RF/ACPA status ( Table 2 ) .
14-1	2035-2044	Regarding	_	_	_	_
14-2	2045-2048	the	abstract[108]	giv[108]	coref	14-18[116_108]
14-3	2049-2059	difference	abstract[108]	giv[108]	_	_
14-4	2060-2062	in	abstract[108]	giv[108]	_	_
14-5	2063-2066	the	abstract[108]|abstract[109]	giv[108]|giv[109]	coref	16-9[134_109]
14-6	2067-2078	β-diversity	abstract[108]|abstract[109]	giv[108]|giv[109]	_	_
14-7	2079-2086	between	abstract[108]	giv[108]	_	_
14-8	2087-2094	healthy	abstract[108]|animal[110]|animal[111]	giv[108]|giv[110]|giv[111]	coref	15-21[131_110]
14-9	2095-2103	subjects	abstract[108]|animal[110]|animal[111]	giv[108]|giv[110]|giv[111]	_	_
14-10	2104-2107	and	abstract[108]|animal[111]	giv[108]|giv[111]	_	_
14-11	2108-2110	RA	abstract[108]|animal[111]|organization|person[113]	giv[108]|giv[111]|giv|giv[113]	coref|coref	15-18|15-18[129_113]
14-12	2111-2119	patients	abstract[108]|animal[111]|person[113]	giv[108]|giv[111]|giv[113]	_	_
14-13	2120-2121	,	_	_	_	_
14-14	2122-2125	the	abstract[115]	giv[115]	coref	14-14[115_0]
14-15	2126-2135	PERMANOVA	abstract|abstract[115]	giv|giv[115]	_	_
14-16	2136-2144	analysis	abstract[115]	giv[115]	_	_
14-17	2145-2151	showed	_	_	_	_
14-18	2152-2153	a	abstract[116]	giv[116]	coref	15-9[126_116]
14-19	2154-2165	significant	abstract[116]	giv[116]	_	_
14-20	2166-2176	difference	abstract[116]	giv[116]	_	_
14-21	2177-2179	in	abstract[116]	giv[116]	_	_
14-22	2180-2190	phenotypes	abstract[116]|abstract[117]	giv[116]|giv[117]	_	_
14-23	2191-2204	characterized	abstract[116]|abstract[117]	giv[116]|giv[117]	_	_
14-24	2205-2207	by	abstract[116]|abstract[117]	giv[116]|giv[117]	_	_
14-25	2208-2217	different	abstract[116]|abstract[117]|abstract[119]	giv[116]|giv[117]|new[119]	_	_
14-26	2218-2225	disease	abstract[116]|abstract[117]|abstract|abstract[119]	giv[116]|giv[117]|new|new[119]	_	_
14-27	2226-2234	activity	abstract[116]|abstract[117]|abstract[119]	giv[116]|giv[117]|new[119]	_	_
14-28	2235-2238	and	abstract[116]|abstract[117]	giv[116]|giv[117]	_	_
14-29	2239-2246	RF/ACPA	abstract[116]|abstract[117]|organization|abstract[121]	giv[116]|giv[117]|giv|giv[121]	_	_
14-30	2247-2253	status	abstract[116]|abstract[117]|abstract[121]	giv[116]|giv[117]|giv[121]	_	_
14-31	2254-2255	(	_	_	_	_
14-32	2256-2261	Table	_	_	_	_
14-33	2262-2263	2	_	_	_	_
14-34	2264-2265	)	_	_	_	_
14-35	2266-2267	.	_	_	_	_

#Text=The weighted UniFrac distance , qualitative measurement of phylogenetic abundance difference , showed a statistical significance between RA patients and healthy subjects .
15-1	2268-2271	The	abstract[123]	new[123]	appos	15-6[124_123]
15-2	2272-2280	weighted	abstract[123]	new[123]	_	_
15-3	2281-2288	UniFrac	abstract|abstract[123]	new|new[123]	_	_
15-4	2289-2297	distance	abstract[123]	new[123]	_	_
15-5	2298-2299	,	_	_	_	_
15-6	2300-2311	qualitative	abstract[124]	giv[124]	_	_
15-7	2312-2323	measurement	abstract[124]	giv[124]	_	_
15-8	2324-2326	of	abstract[124]	giv[124]	_	_
15-9	2327-2339	phylogenetic	abstract[124]|abstract[126]	giv[124]|giv[126]	coref	16-6[133_126]
15-10	2340-2349	abundance	abstract[124]|abstract|abstract[126]	giv[124]|giv|giv[126]	coref	17-18[152_0]
15-11	2350-2360	difference	abstract[124]|abstract[126]	giv[124]|giv[126]	_	_
15-12	2361-2362	,	_	_	_	_
15-13	2363-2369	showed	_	_	_	_
15-14	2370-2371	a	abstract[127]	new[127]	_	_
15-15	2372-2383	statistical	abstract[127]	new[127]	_	_
15-16	2384-2396	significance	abstract[127]	new[127]	_	_
15-17	2397-2404	between	abstract[127]	new[127]	_	_
15-18	2405-2407	RA	abstract[127]|organization|person[129]|person[130]	new[127]|giv|giv[129]|giv[130]	coref|coref|coref	15-18[130_129]|16-12[135_130]|16-37
15-19	2408-2416	patients	abstract[127]|person[129]|person[130]	new[127]|giv[129]|giv[130]	_	_
15-20	2417-2420	and	abstract[127]|person[130]	new[127]|giv[130]	_	_
15-21	2421-2428	healthy	abstract[127]|person[130]|animal[131]	new[127]|giv[130]|giv[131]	coref	17-43[159_131]
15-22	2429-2437	subjects	abstract[127]|person[130]|animal[131]	new[127]|giv[130]|giv[131]	_	_
15-23	2438-2439	.	_	_	_	_

#Text=There was a trend of difference finding in the β-diversity between patients with the lowest and the highest levels of TNF-α or IL-17A , indicating an association of gut microbiota composition with the inflammatory parameters in RA patients .
16-1	2440-2445	There	_	_	_	_
16-2	2446-2449	was	_	_	_	_
16-3	2450-2451	a	abstract[132]	new[132]	_	_
16-4	2452-2457	trend	abstract[132]	new[132]	_	_
16-5	2458-2460	of	abstract[132]	new[132]	_	_
16-6	2461-2471	difference	abstract[132]|abstract[133]	new[132]|giv[133]	_	_
16-7	2472-2479	finding	abstract[132]|abstract[133]	new[132]|giv[133]	_	_
16-8	2480-2482	in	abstract[132]|abstract[133]	new[132]|giv[133]	_	_
16-9	2483-2486	the	abstract[132]|abstract[133]|abstract[134]	new[132]|giv[133]|giv[134]	_	_
16-10	2487-2498	β-diversity	abstract[132]|abstract[133]|abstract[134]	new[132]|giv[133]|giv[134]	_	_
16-11	2499-2506	between	abstract[132]|abstract[133]	new[132]|giv[133]	_	_
16-12	2507-2515	patients	abstract[132]|abstract[133]|person[135]	new[132]|giv[133]|giv[135]	coref	16-37[145_135]
16-13	2516-2520	with	abstract[132]|abstract[133]|person[135]	new[132]|giv[133]|giv[135]	_	_
16-14	2521-2524	the	abstract[132]|abstract[133]|person[135]|abstract[136]	new[132]|giv[133]|giv[135]|giv[136]	_	_
16-15	2525-2531	lowest	abstract[132]|abstract[133]|person[135]|abstract[136]	new[132]|giv[133]|giv[135]|giv[136]	_	_
16-16	2532-2535	and	abstract[132]|abstract[133]|person[135]|abstract[136]	new[132]|giv[133]|giv[135]|giv[136]	_	_
16-17	2536-2539	the	abstract[132]|abstract[133]|person[135]|abstract[136]	new[132]|giv[133]|giv[135]|giv[136]	_	_
16-18	2540-2547	highest	abstract[132]|abstract[133]|person[135]|abstract[136]	new[132]|giv[133]|giv[135]|giv[136]	_	_
16-19	2548-2554	levels	abstract[132]|abstract[133]|person[135]|abstract[136]	new[132]|giv[133]|giv[135]|giv[136]	_	_
16-20	2555-2557	of	abstract[132]|abstract[133]|person[135]|abstract[136]	new[132]|giv[133]|giv[135]|giv[136]	_	_
16-21	2558-2563	TNF-α	abstract[132]|abstract[133]|person[135]|abstract[136]|abstract	new[132]|giv[133]|giv[135]|giv[136]|giv	_	_
16-22	2564-2566	or	abstract[132]|abstract[133]|person[135]|abstract[136]	new[132]|giv[133]|giv[135]|giv[136]	_	_
16-23	2567-2573	IL-17A	abstract[132]|abstract[133]|person[135]|abstract[136]|abstract	new[132]|giv[133]|giv[135]|giv[136]|giv	_	_
16-24	2574-2575	,	abstract[132]	new[132]	_	_
16-25	2576-2586	indicating	abstract[132]	new[132]	_	_
16-26	2587-2589	an	abstract[132]|abstract[139]	new[132]|new[139]	_	_
16-27	2590-2601	association	abstract[132]|abstract[139]	new[132]|new[139]	_	_
16-28	2602-2604	of	abstract[132]|abstract[139]	new[132]|new[139]	_	_
16-29	2605-2608	gut	abstract[132]|abstract[139]|abstract|abstract[142]	new[132]|new[139]|giv|giv[142]	coref|coref	17-9[148_142]|17-13
16-30	2609-2619	microbiota	abstract[132]|abstract[139]|substance|abstract[142]	new[132]|new[139]|giv|giv[142]	coref	17-13[150_0]
16-31	2620-2631	composition	abstract[132]|abstract[139]|abstract[142]	new[132]|new[139]|giv[142]	_	_
16-32	2632-2636	with	abstract[132]	new[132]	_	_
16-33	2637-2640	the	abstract[132]|abstract[143]	new[132]|new[143]	_	_
16-34	2641-2653	inflammatory	abstract[132]|abstract[143]	new[132]|new[143]	_	_
16-35	2654-2664	parameters	abstract[132]|abstract[143]	new[132]|new[143]	_	_
16-36	2665-2667	in	abstract[132]|abstract[143]	new[132]|new[143]	_	_
16-37	2668-2670	RA	abstract[132]|abstract[143]|organization|person[145]	new[132]|new[143]|giv|giv[145]	coref|coref	17-39|17-39[158_145]
16-38	2671-2679	patients	abstract[132]|abstract[143]|person[145]	new[132]|new[143]|giv[145]	_	_
16-39	2680-2681	.	_	_	_	_

#Text=Using pre-trained Naive Bayes Greengenes classifier to explore the taxonomic composition of gut microbiota , we observed an increased abundance of phylum Verrucomicrobiae , which might be driven by the genus Akkermansia ( Akkermansia muciniphila ) , in RA patients compared with healthy subjects .
17-1	2682-2687	Using	_	_	_	_
17-2	2688-2699	pre-trained	object[147]	new[147]	_	_
17-3	2700-2705	Naive	object[147]	new[147]	_	_
17-4	2706-2711	Bayes	abstract[146]|object[147]	new[146]|new[147]	_	_
17-5	2712-2722	Greengenes	abstract[146]|object[147]	new[146]|new[147]	_	_
17-6	2723-2733	classifier	object[147]	new[147]	_	_
17-7	2734-2736	to	_	_	_	_
17-8	2737-2744	explore	_	_	_	_
17-9	2745-2748	the	abstract[148]	giv[148]	_	_
17-10	2749-2758	taxonomic	abstract[148]	giv[148]	_	_
17-11	2759-2770	composition	abstract[148]	giv[148]	_	_
17-12	2771-2773	of	abstract[148]	giv[148]	_	_
17-13	2774-2777	gut	abstract[148]|abstract|substance[150]	giv[148]|giv|giv[150]	coref|coref	20-23|21-13[189_150]
17-14	2778-2788	microbiota	abstract[148]|substance[150]	giv[148]|giv[150]	_	_
17-15	2789-2790	,	_	_	_	_
17-16	2791-2793	we	person	giv	ana	18-1
17-17	2794-2802	observed	_	_	_	_
17-18	2803-2805	an	abstract[152]	giv[152]	_	_
17-19	2806-2815	increased	abstract[152]	giv[152]	_	_
17-20	2816-2825	abundance	abstract[152]	giv[152]	_	_
17-21	2826-2828	of	abstract[152]	giv[152]	_	_
17-22	2829-2835	phylum	abstract[152]|person[153]	giv[152]|giv[153]	coref	21-25[0_153]
17-23	2836-2852	Verrucomicrobiae	abstract[152]|person[153]	giv[152]|giv[153]	_	_
17-24	2853-2854	,	abstract[152]|person[153]	giv[152]|giv[153]	_	_
17-25	2855-2860	which	abstract[152]|person[153]	giv[152]|giv[153]	_	_
17-26	2861-2866	might	abstract[152]|person[153]	giv[152]|giv[153]	_	_
17-27	2867-2869	be	abstract[152]|person[153]	giv[152]|giv[153]	_	_
17-28	2870-2876	driven	abstract[152]|person[153]	giv[152]|giv[153]	_	_
17-29	2877-2879	by	abstract[152]|person[153]	giv[152]|giv[153]	_	_
17-30	2880-2883	the	abstract[152]|person[153]|animal[154]|abstract[155]	giv[152]|giv[153]|giv[154]|new[155]	coref	17-34[0_155]
17-31	2884-2889	genus	abstract[152]|person[153]|animal[154]|abstract[155]	giv[152]|giv[153]|giv[154]|new[155]	_	_
17-32	2890-2901	Akkermansia	abstract[152]|person[153]|abstract[155]	giv[152]|giv[153]|new[155]	_	_
17-33	2902-2903	(	_	_	_	_
17-34	2904-2915	Akkermansia	abstract	giv	coref	19-1
17-35	2916-2927	muciniphila	_	_	_	_
17-36	2928-2929	)	_	_	_	_
17-37	2930-2931	,	_	_	_	_
17-38	2932-2934	in	_	_	_	_
17-39	2935-2937	RA	organization|person[158]	giv|giv[158]	coref|coref	21-19[190_0]|21-30[194_158]
17-40	2938-2946	patients	person[158]	giv[158]	_	_
17-41	2947-2955	compared	person[158]	giv[158]	_	_
17-42	2956-2960	with	person[158]	giv[158]	_	_
17-43	2961-2968	healthy	person[158]|animal[159]	giv[158]|giv[159]	_	_
17-44	2969-2977	subjects	person[158]|animal[159]	giv[158]|giv[159]	_	_
17-45	2978-2979	.	_	_	_	_

#Text=Our findings support the results revealing that the implication of Akkermansia muciniphila in the pathogenesis of murine model of arthritis .
18-1	2980-2983	Our	person|abstract[161]	giv|giv[161]	ana	21-34
18-2	2984-2992	findings	abstract[161]	giv[161]	_	_
18-3	2993-3000	support	_	_	_	_
18-4	3001-3004	the	abstract[162]	giv[162]	_	_
18-5	3005-3012	results	abstract[162]	giv[162]	_	_
18-6	3013-3022	revealing	abstract[162]	giv[162]	_	_
18-7	3023-3027	that	abstract[162]	giv[162]	_	_
18-8	3028-3031	the	abstract[162]|abstract[163]	giv[162]|new[163]	_	_
18-9	3032-3043	implication	abstract[162]|abstract[163]	giv[162]|new[163]	_	_
18-10	3044-3046	of	abstract[162]|abstract[163]	giv[162]|new[163]	_	_
18-11	3047-3058	Akkermansia	abstract[162]|abstract[163]|person|substance[165]	giv[162]|new[163]|new|new[165]	_	_
18-12	3059-3070	muciniphila	abstract[162]|abstract[163]|substance[165]	giv[162]|new[163]|new[165]	_	_
18-13	3071-3073	in	abstract[162]|abstract[163]|substance[165]	giv[162]|new[163]|new[165]	_	_
18-14	3074-3077	the	abstract[162]|abstract[163]|substance[165]|abstract[166]	giv[162]|new[163]|new[165]|new[166]	_	_
18-15	3078-3090	pathogenesis	abstract[162]|abstract[163]|substance[165]|abstract[166]	giv[162]|new[163]|new[165]|new[166]	_	_
18-16	3091-3093	of	abstract[162]|abstract[163]|substance[165]|abstract[166]	giv[162]|new[163]|new[165]|new[166]	_	_
18-17	3094-3100	murine	abstract[162]|abstract[163]|substance[165]|abstract[166]|animal|abstract[168]	giv[162]|new[163]|new[165]|new[166]|new|new[168]	coref	24-15
18-18	3101-3106	model	abstract[162]|abstract[163]|substance[165]|abstract[166]|abstract[168]	giv[162]|new[163]|new[165]|new[166]|new[168]	_	_
18-19	3107-3109	of	abstract[162]|abstract[163]|substance[165]|abstract[166]|abstract[168]	giv[162]|new[163]|new[165]|new[166]|new[168]	_	_
18-20	3110-3119	arthritis	abstract[162]|abstract[163]|substance[165]|abstract[166]|abstract[168]|abstract	giv[162]|new[163]|new[165]|new[166]|new[168]|new	coref	24-18
18-21	3120-3121	.	_	_	_	_

#Text=Akkermansia has also been associated with the proinflammatory pathways , including upregulation of B- and T-cell receptor signaling .
19-1	3122-3133	Akkermansia	abstract	giv	_	_
19-2	3134-3137	has	_	_	_	_
19-3	3138-3142	also	_	_	_	_
19-4	3143-3147	been	_	_	_	_
19-5	3148-3158	associated	_	_	_	_
19-6	3159-3163	with	_	_	_	_
19-7	3164-3167	the	abstract[171]	new[171]	_	_
19-8	3168-3183	proinflammatory	abstract[171]	new[171]	_	_
19-9	3184-3192	pathways	abstract[171]	new[171]	_	_
19-10	3193-3194	,	abstract[171]	new[171]	_	_
19-11	3195-3204	including	abstract[171]	new[171]	_	_
19-12	3205-3217	upregulation	abstract[171]|event[172]	new[171]|new[172]	_	_
19-13	3218-3220	of	abstract[171]|event[172]	new[171]|new[172]	_	_
19-14	3221-3223	B-	abstract[171]|event[172]|abstract|abstract[176]	new[171]|new[172]|new|new[176]	ana	20-8[0_176]
19-15	3224-3227	and	abstract[171]|event[172]|abstract[176]	new[171]|new[172]|new[176]	_	_
19-16	3228-3234	T-cell	abstract[171]|event[172]|abstract|abstract[176]	new[171]|new[172]|new|new[176]	_	_
19-17	3235-3243	receptor	abstract[171]|event[172]|substance|abstract[176]	new[171]|new[172]|new|new[176]	_	_
19-18	3244-3253	signaling	abstract[171]|event[172]|abstract[176]	new[171]|new[172]|new[176]	_	_
19-19	3254-3255	.	_	_	_	_

#Text=These proinflammatory effects may be related to its ability to degrade mucus and thus increase the exposure of resident immune cells to gut microbial antigens .
20-1	3256-3261	These	abstract[177]	new[177]	_	_
20-2	3262-3277	proinflammatory	abstract[177]	new[177]	_	_
20-3	3278-3285	effects	abstract[177]	new[177]	_	_
20-4	3286-3289	may	_	_	_	_
20-5	3290-3292	be	_	_	_	_
20-6	3293-3300	related	_	_	_	_
20-7	3301-3303	to	_	_	_	_
20-8	3304-3307	its	abstract|abstract[179]	giv|new[179]	_	_
20-9	3308-3315	ability	abstract[179]	new[179]	_	_
20-10	3316-3318	to	abstract[179]	new[179]	_	_
20-11	3319-3326	degrade	abstract[179]	new[179]	_	_
20-12	3327-3332	mucus	abstract[179]|substance	new[179]|new	_	_
20-13	3333-3336	and	abstract[179]	new[179]	_	_
20-14	3337-3341	thus	abstract[179]	new[179]	_	_
20-15	3342-3350	increase	abstract[179]	new[179]	_	_
20-16	3351-3354	the	abstract[179]|abstract[181]	new[179]|new[181]	_	_
20-17	3355-3363	exposure	abstract[179]|abstract[181]	new[179]|new[181]	_	_
20-18	3364-3366	of	abstract[179]|abstract[181]	new[179]|new[181]	_	_
20-19	3367-3375	resident	abstract[179]|abstract[181]|animal[182]	new[179]|new[181]|new[182]	_	_
20-20	3376-3382	immune	abstract[179]|abstract[181]|animal[182]	new[179]|new[181]|new[182]	_	_
20-21	3383-3388	cells	abstract[179]|abstract[181]|animal[182]	new[179]|new[181]|new[182]	_	_
20-22	3389-3391	to	abstract[179]|abstract[181]	new[179]|new[181]	_	_
20-23	3392-3395	gut	abstract[179]|abstract[181]|abstract|substance[184]	new[179]|new[181]|giv|new[184]	coref	21-14
20-24	3396-3405	microbial	abstract[179]|abstract[181]|substance[184]	new[179]|new[181]|new[184]	_	_
20-25	3406-3414	antigens	abstract[179]|abstract[181]|substance[184]	new[179]|new[181]|new[184]	_	_
20-26	3415-3416	.	_	_	_	_

#Text=In contrast to previous studies revealing that the predominance of Prevotella in the gut microbiota was associated with the untreated or new-onset RA and phylum Bacteroidetes was enriched in early RA patients , we did not observe significant increase in the abundance of family Prevotellaceae or phylum Bacteroidetes .
21-1	3417-3419	In	_	_	_	_
21-2	3420-3428	contrast	_	_	_	_
21-3	3429-3431	to	_	_	_	_
21-4	3432-3440	previous	abstract[185]	new[185]	_	_
21-5	3441-3448	studies	abstract[185]	new[185]	_	_
21-6	3449-3458	revealing	abstract[185]	new[185]	_	_
21-7	3459-3463	that	abstract[185]	new[185]	_	_
21-8	3464-3467	the	abstract[185]|abstract[186]	new[185]|new[186]	_	_
21-9	3468-3480	predominance	abstract[185]|abstract[186]	new[185]|new[186]	_	_
21-10	3481-3483	of	abstract[185]|abstract[186]	new[185]|new[186]	_	_
21-11	3484-3494	Prevotella	abstract[185]|abstract[186]|abstract	new[185]|new[186]|new	_	_
21-12	3495-3497	in	abstract[185]|abstract[186]	new[185]|new[186]	_	_
21-13	3498-3501	the	abstract[185]|abstract[186]|substance[189]	new[185]|new[186]|giv[189]	_	_
21-14	3502-3505	gut	abstract[185]|abstract[186]|abstract|substance[189]	new[185]|new[186]|giv|giv[189]	_	_
21-15	3506-3516	microbiota	abstract[185]|abstract[186]|substance[189]	new[185]|new[186]|giv[189]	_	_
21-16	3517-3520	was	abstract[185]	new[185]	_	_
21-17	3521-3531	associated	abstract[185]	new[185]	_	_
21-18	3532-3536	with	abstract[185]	new[185]	_	_
21-19	3537-3540	the	abstract[185]|organization[190]	new[185]|giv[190]	coref	21-31[0_190]
21-20	3541-3550	untreated	abstract[185]|organization[190]	new[185]|giv[190]	_	_
21-21	3551-3553	or	abstract[185]|organization[190]	new[185]|giv[190]	_	_
21-22	3554-3563	new-onset	abstract[185]|organization[190]	new[185]|giv[190]	_	_
21-23	3564-3566	RA	abstract[185]|organization[190]	new[185]|giv[190]	_	_
21-24	3567-3570	and	abstract[185]	new[185]	_	_
21-25	3571-3577	phylum	abstract[185]|person	new[185]|giv	coref	21-47
21-26	3578-3591	Bacteroidetes	abstract[185]|abstract	new[185]|new	coref	21-47[201_0]
21-27	3592-3595	was	abstract[185]	new[185]	_	_
21-28	3596-3604	enriched	abstract[185]	new[185]	_	_
21-29	3605-3607	in	_	_	_	_
21-30	3608-3613	early	person[194]	giv[194]	coref	22-4[203_194]
21-31	3614-3616	RA	organization|person[194]	giv|giv[194]	coref	23-6
21-32	3617-3625	patients	person[194]	giv[194]	_	_
21-33	3626-3627	,	_	_	_	_
21-34	3628-3630	we	person	giv	ana	22-11
21-35	3631-3634	did	_	_	_	_
21-36	3635-3638	not	_	_	_	_
21-37	3639-3646	observe	_	_	_	_
21-38	3647-3658	significant	abstract[196]	new[196]	_	_
21-39	3659-3667	increase	abstract[196]	new[196]	_	_
21-40	3668-3670	in	abstract[196]	new[196]	_	_
21-41	3671-3674	the	abstract[196]|abstract[197]	new[196]|new[197]	_	_
21-42	3675-3684	abundance	abstract[196]|abstract[197]	new[196]|new[197]	_	_
21-43	3685-3687	of	abstract[196]|abstract[197]	new[196]|new[197]	_	_
21-44	3688-3694	family	abstract[196]|abstract[197]|abstract|abstract[199]	new[196]|new[197]|new|new[199]	_	_
21-45	3695-3709	Prevotellaceae	abstract[196]|abstract[197]|abstract[199]	new[196]|new[197]|new[199]	_	_
21-46	3710-3712	or	abstract[196]|abstract[197]	new[196]|new[197]	_	_
21-47	3713-3719	phylum	abstract[196]|abstract[197]|person|abstract[201]	new[196]|new[197]|giv|giv[201]	_	_
21-48	3720-3733	Bacteroidetes	abstract[196]|abstract[197]|abstract[201]	new[196]|new[197]|giv[201]	_	_
21-49	3734-3735	.	_	_	_	_

#Text=The differences in patients ’ characteristics and treatment regimens of our enrolled patients may explain this discrepancy .
22-1	3736-3739	The	abstract[202]	new[202]	_	_
22-2	3740-3751	differences	abstract[202]	new[202]	_	_
22-3	3752-3754	in	abstract[202]	new[202]	_	_
22-4	3755-3763	patients	abstract[202]|person[203]|abstract[204]	new[202]|giv[203]|new[204]	coref	22-11[208_203]
22-5	3764-3765	’	abstract[202]|person[203]|abstract[204]	new[202]|giv[203]|new[204]	_	_
22-6	3766-3781	characteristics	abstract[202]|abstract[204]	new[202]|new[204]	_	_
22-7	3782-3785	and	abstract[202]	new[202]	_	_
22-8	3786-3795	treatment	abstract[202]|abstract|abstract[206]	new[202]|new|new[206]	_	_
22-9	3796-3804	regimens	abstract[202]|abstract[206]	new[202]|new[206]	_	_
22-10	3805-3807	of	abstract[202]|abstract[206]	new[202]|new[206]	_	_
22-11	3808-3811	our	abstract[202]|abstract[206]|person|person[208]	new[202]|new[206]|giv|giv[208]	coref	23-5[212_208]
22-12	3812-3820	enrolled	abstract[202]|abstract[206]|person[208]	new[202]|new[206]|giv[208]	_	_
22-13	3821-3829	patients	abstract[202]|abstract[206]|person[208]	new[202]|new[206]|giv[208]	_	_
22-14	3830-3833	may	_	_	_	_
22-15	3834-3841	explain	_	_	_	_
22-16	3842-3846	this	abstract[209]	new[209]	ana	23-1[0_209]
22-17	3847-3858	discrepancy	abstract[209]	new[209]	_	_
22-18	3859-3860	.	_	_	_	_

#Text=It is interesting that active RA patients have an increased abundance of Collinsella compared with inactive RA patients .
23-1	3861-3863	It	abstract	giv	_	_
23-2	3864-3866	is	_	_	_	_
23-3	3867-3878	interesting	_	_	_	_
23-4	3879-3883	that	_	_	_	_
23-5	3884-3890	active	person[212]	giv[212]	_	_
23-6	3891-3893	RA	organization|person[212]	giv|giv[212]	coref	23-17
23-7	3894-3902	patients	person[212]	giv[212]	_	_
23-8	3903-3907	have	_	_	_	_
23-9	3908-3910	an	abstract[213]	new[213]	_	_
23-10	3911-3920	increased	abstract[213]	new[213]	_	_
23-11	3921-3930	abundance	abstract[213]	new[213]	_	_
23-12	3931-3933	of	abstract[213]	new[213]	_	_
23-13	3934-3945	Collinsella	abstract[213]|animal	new[213]|new	coref	24-5
23-14	3946-3954	compared	_	_	_	_
23-15	3955-3959	with	_	_	_	_
23-16	3960-3968	inactive	person[216]	new[216]	_	_
23-17	3969-3971	RA	organization|person[216]	giv|new[216]	coref	26-15[239_0]
23-18	3972-3980	patients	person[216]	new[216]	_	_
23-19	3981-3982	.	_	_	_	_

#Text=The arthrogenic role of Collinsella has been confirmed both in vivo using a humanized murine model of arthritis and in vitro by a human intestinal epithelium cell-based study .
24-1	3983-3986	The	abstract[217]	new[217]	_	_
24-2	3987-3998	arthrogenic	abstract[217]	new[217]	_	_
24-3	3999-4003	role	abstract[217]	new[217]	_	_
24-4	4004-4006	of	abstract[217]	new[217]	_	_
24-5	4007-4018	Collinsella	abstract[217]|animal	new[217]|giv	coref	25-7
24-6	4019-4022	has	_	_	_	_
24-7	4023-4027	been	_	_	_	_
24-8	4028-4037	confirmed	_	_	_	_
24-9	4038-4042	both	abstract[219]	new[219]	_	_
24-10	4043-4045	in	abstract[219]	new[219]	_	_
24-11	4046-4050	vivo	abstract[219]	new[219]	_	_
24-12	4051-4056	using	_	_	_	_
24-13	4057-4058	a	abstract[221]	new[221]	coref	25-20[233_221]
24-14	4059-4068	humanized	abstract[221]	new[221]	_	_
24-15	4069-4075	murine	animal|abstract[221]	giv|new[221]	coref	25-21
24-16	4076-4081	model	abstract[221]	new[221]	_	_
24-17	4082-4084	of	abstract[221]	new[221]	_	_
24-18	4085-4094	arthritis	abstract[221]|abstract	new[221]|giv	coref	25-18
24-19	4095-4098	and	_	_	_	_
24-20	4099-4101	in	_	_	_	_
24-21	4102-4107	vitro	organization	new	_	_
24-22	4108-4110	by	_	_	_	_
24-23	4111-4112	a	abstract[226]	giv[226]	_	_
24-24	4113-4118	human	abstract[226]	giv[226]	_	_
24-25	4119-4129	intestinal	place[224]|abstract[226]	new[224]|giv[226]	_	_
24-26	4130-4140	epithelium	place[224]|abstract[226]	new[224]|giv[226]	_	_
24-27	4141-4151	cell-based	abstract|abstract[226]	new|giv[226]	_	_
24-28	4152-4157	study	abstract[226]	giv[226]	_	_
24-29	4158-4159	.	_	_	_	_

#Text=Chen et al. further demonstrated that Collinsella could be transferred to germ-free mice with resultant exacerbation of arthritis in a murine model .
25-1	4160-4164	Chen	person	giv	_	_
25-2	4165-4167	et	_	_	_	_
25-3	4168-4171	al.	_	_	_	_
25-4	4172-4179	further	_	_	_	_
25-5	4180-4192	demonstrated	_	_	_	_
25-6	4193-4197	that	_	_	_	_
25-7	4198-4209	Collinsella	animal	giv	coref	26-9
25-8	4210-4215	could	_	_	_	_
25-9	4216-4218	be	_	_	_	_
25-10	4219-4230	transferred	_	_	_	_
25-11	4231-4233	to	_	_	_	_
25-12	4234-4243	germ-free	animal[229]	new[229]	_	_
25-13	4244-4248	mice	animal[229]	new[229]	_	_
25-14	4249-4253	with	_	_	_	_
25-15	4254-4263	resultant	event[230]	new[230]	_	_
25-16	4264-4276	exacerbation	event[230]	new[230]	_	_
25-17	4277-4279	of	event[230]	new[230]	_	_
25-18	4280-4289	arthritis	event[230]|abstract	new[230]|giv	_	_
25-19	4290-4292	in	event[230]	new[230]	_	_
25-20	4293-4294	a	event[230]|abstract[233]	new[230]|giv[233]	_	_
25-21	4295-4301	murine	event[230]|animal|abstract[233]	new[230]|giv|giv[233]	_	_
25-22	4302-4307	model	event[230]|abstract[233]	new[230]|giv[233]	_	_
25-23	4308-4309	.	_	_	_	_

#Text=These observations suggest a potential role of the Collinsella expansion in the pathogenesis of active RA .
26-1	4310-4315	These	abstract[234]	new[234]	_	_
26-2	4316-4328	observations	abstract[234]	new[234]	_	_
26-3	4329-4336	suggest	_	_	_	_
26-4	4337-4338	a	abstract[235]	new[235]	_	_
26-5	4339-4348	potential	abstract[235]	new[235]	_	_
26-6	4349-4353	role	abstract[235]	new[235]	_	_
26-7	4354-4356	of	abstract[235]	new[235]	_	_
26-8	4357-4360	the	abstract[235]|event[237]	new[235]|new[237]	_	_
26-9	4361-4372	Collinsella	abstract[235]|animal|event[237]	new[235]|giv|new[237]	_	_
26-10	4373-4382	expansion	abstract[235]|event[237]	new[235]|new[237]	_	_
26-11	4383-4385	in	abstract[235]	new[235]	_	_
26-12	4386-4389	the	abstract[235]|abstract[238]	new[235]|new[238]	_	_
26-13	4390-4402	pathogenesis	abstract[235]|abstract[238]	new[235]|new[238]	_	_
26-14	4403-4405	of	abstract[235]|abstract[238]	new[235]|new[238]	_	_
26-15	4406-4412	active	abstract[235]|abstract[238]|organization[239]	new[235]|new[238]|giv[239]	_	_
26-16	4413-4415	RA	abstract[235]|abstract[238]|organization[239]	new[235]|new[238]|giv[239]	_	_
26-17	4416-4417	.	_	_	_	_
